A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
Key facts
- Who runs it
- Pfizer
- Where
- Albuquerque, Cincinnati, Columbia, Columbus, Detroit, Fort Lauderdale, Gilbert, Grosse Pointe Woods, Honolulu, Iowa City, Lenexa, Meridian, Mesa, Miami, New York, Norfolk, Omaha, Palo Alto, Reno, Rochester, San Antonio, Silver Spring, Somers Point, Tomball, Walnut Creek, Washington D.C., and Wilmington, United StatesSee the 35 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 484 people enrolled
- Started
- 25 Jan 2023
- Ended
- 23 Sept 2025
- Type of study
- Interventional, 14 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
- Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- Candidate 3: PF-07921186: VZV modRNA Suspension for Injection
- Shingrix
- Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
- Record updated
- 4 May 2026
- Why it stopped
- Strategic decision made by the company
Who can take part
- Age
- 50 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 47 criteriaShow less
Who can take part
- Male or female participants 50 through 69 years of age (inclusive) at the time of consent
- Healthy participants who are determined by clinical assessment, including medical history and clinical judgment of the investigator, to be eligible for inclusion in the study. Note: Known infection with HIV, HCV or HBV is an exclusion in Substudy A
- Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol; Substudy A: Group 11 to Group 14
- Male or female participants 50 through 69 years of age (inclusive) at the time of consent
- Healthy participants who are determined by clinical assessment, including medical history and clinical judgment of the investigator, to be eligible for inclusion in the study. Note: Known infection with HIV, HCV or HBV is an exclusion in Substudy A
- Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol
- Has a body mass index (BMI) between 18 and 35 (inclusive) kg/m2 at the screening visit; Substudy A: Group 1 to Group 10
- Male or female participants 50 through 85 years of age (inclusive) at the time of consent
- Healthy participants who are determined by clinical assessment, including medical history and clinical judgment of the investigator, to be eligible for inclusion in the study
- Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol
- Has a BMI between 18 and 35 (inclusive) kg/m2 at the screening visit
Who cannot take part
- Prior history of heart disease (eg, heart failure, recent coronary artery disease, cardiomyopathies, pericarditis/myocarditis)
- Previous vaccination with any varicella or HZ vaccine
- Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study
- Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study
- Any participant who has received or plans to receive an RNA vaccine 28 days prior to Vaccination 1
- Participation in other interventional studies within 28 days prior to study entry or anticipated involvement through and including 6 months after the last dose of study intervention. Participation in observational studies is permitted
- Participation or planned participation in strenuous or endurance exercise within 7 days before or after each study intervention administration
- Prior history of heart disease (eg, heart failure, recent coronary artery disease, cardiomyopathies, pericarditis, or myocarditis)
- Previous vaccination with any varicella or HZ vaccine
- Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study
- Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study
- Any participant who has received or plans to receive an RNA vaccine 28 days prior to Vaccination 1
- Participation in other interventional studies within 28 days prior to study entry or anticipated involvement through and including 6 months after the last dose of study intervention is prohibited. Participation in observational studies is permitted
- History of HZ (shingles)
- History of Guillain-Barré syndrome
- Known infection with HIV, HCV, or HBV
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
- History of HZ (shingles)
- History of Guillain-Barré syndrome
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality; or any abnormal bilirubin or troponin I value
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Women who are pregnant or breastfeeding
- Screening 12-lead ECG that, as judged by the investigator, is consistent with probable or possible myocarditis/pericarditis or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
- Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members; SubStudy B:
- Women who are pregnant or breastfeeding
- Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
Other criteria
- Substudy A: Group 1 to Group 10
Where in United States
- IMA Clinical ResearchAlbuquerque, United States
- CTI Clinical Research CenterCincinnati, United States
- Centennial Medical GroupColumbia, United States
- Centricity Research Columbus Ohio MultispecialtyColumbus, United States
- Columbus Cardiovascular Associates, Inc.Columbus, United States
- C.S. Mott Clinical Research Center (CRC)Detroit, United States
- Proactive Clinical Research,LLCFort Lauderdale, United States
- Tri-City CardiologyGilbert, United States
- Henry Ford St. John HospitalGrosse Pointe Woods, United States
- East-West Medical Research InstituteHonolulu, United States
- University of IowaIowa City, United States
- Johnson County Clinical TrialsLenexa, United States
- Solaris Clinical ResearchMeridian, United States
- West Valley Cardiology ServicesMeridian, United States
- Aventiv Research, IncMesa, United States
- Acevedo Clinical Research AssociatesMiami, United States
- Icahn School of Medicine at Mount SinaiNew York, United States
- NYU Langone HealthNew York, United States
- Tisch HospitalNew York, United States
- Velocity Clinical Research - NorfolkNorfolk, United States
- Quality Clinical ResearchOmaha, United States
- Stanford University Medical CenterPalo Alto, United States
- University of Nevada School of Medicine - RenoReno, United States
- Rochester Clinical Research, LLCRochester, United States
- Clinical Trials of Texas LLCSan Antonio, United States
- Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, United States
- IMA Clinical Research San AntonioSan Antonio, United States
- Associates in Cardiology PASilver Spring, United States
- South Jersey Infectious DiseaseSomers Point, United States
- Dynamed Clinical Research, LP d/b/a DM Clinical ResearchTomball, United States
- Diablo Clinical Research, Inc.Walnut Creek, United States
- GW Medical Faculty AssociatesWashington D.C., United States
- GW Vaccine Research UnitWashington D.C., United States
- Accellacare - WilmingtonWilmington, United States
- Wilmington Health, PLLC (Cardiologist)Wilmington, United States
About the trial
What the trial wants to find out
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants 50 through 85 years of age.
Read full original descriptionShow less
This study will be conducted in 2 substudies: Substudy A (Phase 1) and Substudy B (Phase 2).
Substudy A:
This substudy is the Phase 1 portion of the study. In this substudy, participants will receive 1 of 3 VZV modRNA vaccine candidates (different construct, different dose levels and different formulation [frozen or freeze dry powder]) or the approved shingles vaccine intramuscularly.
Participants will be assigned in 1 of 10 groups in the study. Vaccination will be given either as a 2-dose series using one of two dosing schedules (either 2-months apart or 6-months apart), or (in one of the groups), as a single VZV modRNA vaccine at the first vaccination visit and saline at the second vaccination visit.
Participants will take part in this study for 8 to 12 months depending on the group they are assigned to. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants assigned to these selected groups will be involved in the study for up to 5 years.
Substudy B:
This substudy is the Phase 2 portion of the study. In this part of the study, participants will receive either VZV modRNA vaccine at selected dose level/schedule/formulation or approved shingles vaccine. This selection was determined from data collected in Substudy A.
Participants will be involved in this study for up to 5 years.
The 14 groups in the trial
- SubStudy A (SSA): Group 1Treatment being tested
Candidate 1, Dose Level 1, lyophilized, 0, 2 months schedule
Treatment: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- SSA: Group 2Treatment being tested
Candidate 1, Dose Level 2, lyophilized, 0, 2 months schedule
Treatment: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- SSA: Group 3Treatment being tested
Candidate 1, Dose Level 3, lyophilized, 0, 2 months schedule
Treatment: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- SSA: Group 4Treatment being tested
Candidate 1, Dose Level 2, frozen, 0, 2 months schedule
Treatment: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
- SSA: Group 5Treatment being tested
Candidate 1, Dose Level 2, Frozen, 0, 6 months schedule
Treatment: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
- SSA: Group 6Treatment being tested
Candidate 2, frozen, 0, 2 months schedule
Treatment: Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- SSA: Group 7Treatment being tested
Candidate 3, Frozen, 0, 2 months schedule
Treatment: Candidate 3: PF-07921186: VZV modRNA Suspension for Injection
- SSA: Group 8Existing treatment, for comparison
Shingrix, 0, 2 months schedule
Treatment: Shingrix
- SSA: Group 9Existing treatment, for comparison
Shingrix, 0, 6 months schedule
Treatment: Shingrix
- SSA: Group 10Treatment being tested
Candidate 1, Dose level 4, lyophilized, 0, 6 months schedule (saline at month 6)
Treatment: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- Substudy B (SSB): Group 1Treatment being tested
Candidate 2, Dose level 3, lyophilized, 0, 2 months schedule
Treatment: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
- SSB: Group 2Treatment being tested
Candidate 2, Dose level 4, lyophilized, 0, 2 months schedule
Treatment: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
- SSB: Group 3Treatment being tested
Candidate 2, Dose level 4, lyophilized, 0, 2 months schedule (saline at month 2)
Treatment: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
- SSB: Group 4Existing treatment, for comparison
Shingrix, 0, 2 months schedule
Treatment: Shingrix
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS
- Record updated
- 4 May 2026